antiemetics

Summary

Summary: Drugs used to prevent NAUSEA or VOMITING. Antiemetics act by a wide range of mechanisms. Some act on the medullary control centers (the vomiting center and the chemoreceptive trigger zone) while others affect the peripheral receptors.

Top Publications

  1. ncbi Prevention and treatment of postoperative nausea and vomiting
    A L Kovac
    Department of Anaesthesiology, University of Kansas Medical Center, Kansas City 66160 7415, USA
    Drugs 59:213-43. 2000
  2. doi Chemotherapy-induced nausea and vomiting
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center, Boston, MA 02135, USA
    N Engl J Med 358:2482-94. 2008
  3. pmc A factorial trial of six interventions for the prevention of postoperative nausea and vomiting
    Christian C Apfel
    Julius Maximilians Universitat, Wurzburg, Germany
    N Engl J Med 350:2441-51. 2004
  4. ncbi Antiemetics: American Society of Clinical Oncology clinical practice guideline update
    Ethan Basch
    Memorial Sloan Kettering Cancer Center, New York, USA
    J Clin Oncol 29:4189-98. 2011
  5. ncbi Update and new trends in antiemetic therapy: the continuing need for novel therapies
    P Feyer
    Department of Radiooncology, Nuclear Medicine, Vivantes Clinics Berlin Neukölln, Berlin
    Ann Oncol 22:30-8. 2011
  6. ncbi Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron
    Peter Eisenberg
    California Cancer Care, Greenbrae, California, USA
    Cancer 98:2473-82. 2003
  7. ncbi Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor
    Camilo Rojas
    Research and Translational Development, MGI PHARMA INC, 6611 Tributary St, Baltimore, MD 21224 6515, USA
    Anesth Analg 107:469-78. 2008
  8. ncbi Optimal timing of acustimulation for antiemetic prophylaxis as an adjunct to ondansetron in patients undergoing plastic surgery
    Paul F White
    Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9068, USA
    Anesth Analg 100:367-72. 2005
  9. ncbi A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting
    Keith A Candiotti
    Department of Anesthesiology, University of Miami, Miami, Florida, USA
    Anesth Analg 107:445-51. 2008
  10. ncbi The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
    M Aapro
    Medical Oncology and Radiation, IMO Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 23:1986-92. 2012

Research Grants

  1. Structure of the GABA-A Receptor Binding Sites
    CYNTHIA M CZAJKOWSKI; Fiscal Year: 2012
  2. Structure of the GABA-A Receptor Binding Sites
    CYNTHIA M CZAJKOWSKI; Fiscal Year: 2013
  3. Pharmacological modulation of synapses and cognition during HIV-1 neurotoxicity
    Stanley A Thayer; Fiscal Year: 2013
  4. Treating Chemotherapy Induced Nausea with Acupressure
    Suzanne Dibble; Fiscal Year: 2003
  5. PHARMACOLOGY OF LEUCOVORIN IN CANCER CHEMOTHERAPY
    Douglas Greene; Fiscal Year: 1980
  6. Transmucosal oral diphenhydramine-rapid relief of nausea
    EDWARD CONE; Fiscal Year: 2001
  7. CANCER CENTER CALGB PARTICIPATION
    Hyman Muss; Fiscal Year: 2002
  8. INTESTINAL ION TRANSPORT--SUBMUCOUS NEURONS
    Annmarie Surprenant; Fiscal Year: 1992
  9. MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONS
    NISSAR DARMANI; Fiscal Year: 2007
  10. Outcomes After ACL Reconstruction: Femoral Nerve Block
    Brian Williams; Fiscal Year: 2005

Detail Information

Publications312 found, 100 shown here

  1. ncbi Prevention and treatment of postoperative nausea and vomiting
    A L Kovac
    Department of Anaesthesiology, University of Kansas Medical Center, Kansas City 66160 7415, USA
    Drugs 59:213-43. 2000
    ..Commonly used older, traditional antiemetics for PONV include the anticholinergics (scopolamine), phenothiazines (promethazine), antihistamines (..
  2. doi Chemotherapy-induced nausea and vomiting
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center, Boston, MA 02135, USA
    N Engl J Med 358:2482-94. 2008
  3. pmc A factorial trial of six interventions for the prevention of postoperative nausea and vomiting
    Christian C Apfel
    Julius Maximilians Universitat, Wurzburg, Germany
    N Engl J Med 350:2441-51. 2004
    ..Although many trials have been conducted, the relative benefits of prophylactic antiemetic interventions given alone or in combination remain unknown...
  4. ncbi Antiemetics: American Society of Clinical Oncology clinical practice guideline update
    Ethan Basch
    Memorial Sloan Kettering Cancer Center, New York, USA
    J Clin Oncol 29:4189-98. 2011
    To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology.
  5. ncbi Update and new trends in antiemetic therapy: the continuing need for novel therapies
    P Feyer
    Department of Radiooncology, Nuclear Medicine, Vivantes Clinics Berlin Neukölln, Berlin
    Ann Oncol 22:30-8. 2011
    ..This review focuses on the current understanding of CINV, problems associated with its management and the status of promising antiemetic therapies...
  6. ncbi Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron
    Peter Eisenberg
    California Cancer Care, Greenbrae, California, USA
    Cancer 98:2473-82. 2003
    ..The current Phase III trial evaluated the efficacy and safety of palonosetron in preventing acute and delayed CINV after moderately emetogenic chemotherapy...
  7. ncbi Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor
    Camilo Rojas
    Research and Translational Development, MGI PHARMA INC, 6611 Tributary St, Baltimore, MD 21224 6515, USA
    Anesth Analg 107:469-78. 2008
    ..However, these attributes alone are not sufficient to explain the results with palonosetron. We sought to elucidate additional differences among 5-HT(3)-RAs that could help explain the observations in the clinic...
  8. ncbi Optimal timing of acustimulation for antiemetic prophylaxis as an adjunct to ondansetron in patients undergoing plastic surgery
    Paul F White
    Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9068, USA
    Anesth Analg 100:367-72. 2005
    ..The incidence of vomiting/retching and the need for rescue antiemetics were determined at specific time intervals for up to 72 h after surgery...
  9. ncbi A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting
    Keith A Candiotti
    Department of Anesthesiology, University of Miami, Miami, Florida, USA
    Anesth Analg 107:445-51. 2008
    ....
  10. ncbi The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
    M Aapro
    Medical Oncology and Radiation, IMO Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 23:1986-92. 2012
    ..Our objective was to evaluate the effect of guideline-consistent CINV prophylaxis (GCCP) on patient outcomes...
  11. ncbi Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting
    Thein H Oo
    Caritas St Elizabeth s Medical Center and Tufts University School of Medicine, Boston, MA 02135, USA
    Nat Clin Pract Oncol 2:196-201. 2005
    ..Recently, two new antiemetics, aprepitant, the first member of the neurokinin-1 antagonists, and palonosetron, a second-generation 5-..
  12. ncbi Mechanisms of reducing postoperative pain, nausea and vomiting: a systematic review of current techniques
    Alex Rawlinson
    Department of Surgery, Northampton General Hospital, Northampton, UK
    Evid Based Med 17:75-80. 2012
    ..The objective of this systematic review was to assess how single-modality evidence-based care principles, regarding postoperative analgesia and postoperative nausea and vomiting (PONV) prophylaxis, combine to achieve this...
  13. ncbi Guideline for the management of postoperative nausea and vomiting
    Geoff McCracken
    Toronto ON, Canada
    J Obstet Gynaecol Can 30:600-7, 608-16. 2008
    ..Recognizing that we must work as a team to optimize the care of our patients perioperatively, this guideline was written in partnership with anaesthesiologists...
  14. ncbi Palonosetron: in the prevention of nausea and vomiting
    Lily P H Yang
    Adis, North Shore, Auckland, New Zealand
    Drugs 69:2257-78. 2009
    ..Intravenous palonosetron is a useful alternative to currently recommended agents in PONV prevention...
  15. ncbi Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Mehdi Hamadani
    Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43228, US
    J Oncol Pharm Pract 13:69-75. 2007
    ....
  16. ncbi Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials
    M R Tramer
    Nuffield Department of Anaesthetics, The Churchill, and Oxford Radcliffe Hospital, United Kingdom
    Anesthesiology 87:1277-89. 1997
    ..The authors reviewed efficacy and safety data for ondansetron for preventing postoperative nausea and vomiting (PONV)...
  17. ncbi Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
    Mitsue Saito
    Department of Breast Oncology, Juntendo University Hospital, Tokyo, Japan
    Lancet Oncol 10:115-24. 2009
    ....
  18. ncbi Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
    M Aapro
    Division of Oncology, Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Genolier, Switzerland
    Ann Oncol 21:1083-8. 2010
    ..We evaluated the possibility to reduce the total dose of corticosteroids when palonosetron, a long-acting second-generation 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonist, is used...
  19. ncbi Prophylactic control of post-operative nausea and vomiting using ondansetron and ramosetron after cardiac surgery
    D K Choi
    Department of Anesthesiology and Pain Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea
    Acta Anaesthesiol Scand 54:962-9. 2010
    ..The aim of this study was to evaluate the efficacy of ondansetron and ramosetron in the reduction of post-operative nausea and vomiting (PONV) associated with patient-controlled analgesia (PCA) after cardiac surgery...
  20. ncbi Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review
    M R Tramer
    Department APSIC, Geneva University Hospital, Switzerland
    Anesth Analg 88:1354-61. 1999
    ..At 24 h, the cumulative incidence of nausea and vomiting without antiemetics was approximately 50%. Droperidol 0.017-0.17 mg/mg of morphine (0...
  21. pmc Motherisk update. Is ondansetron safe for use during pregnancy?
    Gideon Koren
    Department of Medicine, University of Western Ontario, London, Ontario
    Can Fam Physician 58:1092-3. 2012
    ..I have read some new precautions recommended by the US Food and Drug Administration (FDA). Is ondansetron safe to use during pregnancy?..
  22. ncbi The impact of prophylactic dexamethasone on nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis
    Paul J Karanicolas
    Department of Surgery, University of Western Ontario, London, Canada
    Ann Surg 248:751-62. 2008
    ..To determine the impact of prophylactic corticosteroid administration on postoperative nausea, vomiting, pain and complications in patients undergoing laparoscopic cholecystectomy...
  23. ncbi Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis
    Tobias Engel Ayer Botrel
    Rua Tranquillo Prosperi, 143, Campinas, Sao Paulo, 13084 778, Brazil
    Support Care Cancer 19:823-32. 2011
    ..25 mg with other 5-HT(3)R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy...
  24. ncbi Aprepitant: drug-drug interactions in perspective
    M S Aapro
    Institut Multidisciplinaire d Oncologie, Clinique de Genolier, Switzerland
    Ann Oncol 21:2316-23. 2010
    ..Therefore, the concern of negative interactions remains largely theoretical but needs to be verified with new agents extensively metabolized through the 3A4 pathway...
  25. ncbi [Nausea and vomiting in the postoperative phase. Expert- and evidence-based recommendations for prophylaxis and therapy]
    C C Apfel
    Perioperative Clinical Research Core, Department of Anesthesia and Perioperative Care, University of California, San Francisco, UCSF Medical Center at Mt Zion, 1600 Divisadero, C 355, San Francisco, California 94115 1605, USA
    Anaesthesist 56:1170-80. 2007
    ..This appears to be true for total intravenous anesthesia (TIVA) as well as for dexamethasone and other antiemetics; assuming a sufficiently high, adequate and equipotent dosage which should be weight-adjusted in children...
  26. ncbi Antiemetic guidelines: creating a more practical treatment approach
    Jim M Koeller
    University of Texas Health Science Center at San Antonio, Pharmacotherapy MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Support Care Cancer 10:519-22. 2002
    ..creation of the original guidelines convened to try to create a simpler, more practical approach to the use of antiemetics in preventing chemotherapy-induced nausea and vomiting...
  27. ncbi A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia
    Stephen H Raymond
    Department of Obstetrics and Gynaecology, Royal Hobart Hospital, Hobart, Tasmania, Australia
    Aust N Z J Obstet Gynaecol 53:358-62. 2013
    ..There is an impression of poor management of pregnancy sickness in Australia, specifically an apparent total reliance on metoclopramide, as a first-line choice...
  28. ncbi Transcutaneous acupoint electrical stimulation with the ReliefBand for the prevention of nausea and vomiting during and after cesarean delivery under spinal anesthesia
    Ashraf S Habib
    Department of Anesthesiology, Box 3094, Duke University Medical Center, Durham, NC, 27710
    Anesth Analg 102:581-4. 2006
    ..nausea (30% versus 43%/23% versus 41%), vomiting (13% versus 9%/26 versus 37%), need for rescue antiemetics (23% versus 18%/34% versus 39%), or complete response (55% versus 57%/51% versus 34%)...
  29. ncbi Ondansetron in pregnancy and risk of adverse fetal outcomes
    Björn Pasternak
    Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
    N Engl J Med 368:814-23. 2013
    ..Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied...
  30. ncbi The effects of P6 electrical acustimulation on postoperative nausea and vomiting in patients after infratentorial craniotomy
    Ming Xu
    Department of Anesthesiology, Huashan Hospital, Fudan University, Shanghai, China
    J Neurosurg Anesthesiol 24:312-6. 2012
    ..We evaluated the effectiveness of transcutaneous electrical acupoint stimulation (TEAS) at P6 for the prophylaxis of PONV in patients undergoing infratentorial craniotomy...
  31. ncbi Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment
    Brigitte Bloechl-Daum
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 24:4472-8. 2006
    ....
  32. pmc Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
    M de Boer Dennert
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital, The Netherlands
    Br J Cancer 76:1055-61. 1997
    ..Presently, these antiemetics are routinely used as concomitant therapy in emetogenic chemotherapy regimens...
  33. ncbi Dexamethasone has a central antiemetic mechanism in decerebrated cats
    Chiu Ming Ho
    Department of Anesthesiology, National Defense Medical Center Tri Service General Hospital, Rm 8113, No 161, Sec 6, Minchiuan E Rd, Taipei 114, Taiwan
    Anesth Analg 99:734-9, table of contents. 2004
    ..These results suggest that dexamethasone exerts its central antiemetic action through an activation of the glucocorticoid receptors in the bilateral nuclei tractus solitarii in the medulla...
  34. ncbi Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E214, Burlington, VT 05405, USA
    Support Care Cancer 19:S43-7. 2011
    ..Additional efforts will be necessary to understand mechanisms of nausea and to identify optimal remedies...
  35. ncbi A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting
    Tong J Gan
    Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
    Anesth Analg 99:1070-5, table of contents. 2004
    ..Stimulation at P6 also has analgesic effects...
  36. ncbi Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting
    Thomas A Burke
    Global Outcomes Research, Oncology, Global Human Health, Merck and Co, Inc, One Merck Drive, WS2E 76, Whitehouse Station, NJ 08889, USA
    Support Care Cancer 19:131-40. 2011
    ..This study was conducted to describe CINV-associated healthcare visits and costs following a first cycle of highly or moderately emetogenic chemotherapy (HEC or MEC)...
  37. ncbi Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe
    Anup K Majumdar
    Merck Research Laboratories, West Point, PA 19422, USA
    Clin Pharmacol Ther 74:150-6. 2003
    ..The effect of aprepitant on in vivo CYP3A4 activity in humans with oral midazolam used as a sensitive probe of CYP3A4 activity was evaluated in this study...
  38. ncbi Consensus guidelines for managing postoperative nausea and vomiting
    Tong J Gan
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Anesth Analg 97:62-71, table of contents. 2003
    ..We present evidence-based guidelines developed by an international panel of experts for the management of postoperative nausea and vomiting...
  39. ncbi Electroacupoint stimulation for postoperative nausea and vomiting in patients undergoing supratentorial craniotomy
    Xiao qiang Wang
    Department of Neurosurgery, Huashan Hospital of Fudan University, Shanghai, China
    J Neurosurg Anesthesiol 22:128-31. 2010
    ..We evaluated the effectiveness of transcutaneous electrical acupoint stimulation (TEAS) at the P6 acupoint for prevention of postoperative nausea and vomiting in patients undergoing supratentorial craniotomy...
  40. pmc Combination of antiemetics for the prevention of postoperative nausea and vomiting in high-risk patients
    Eun Jin Kim
    Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Korean Med Sci 22:878-82. 2007
    ..very high-risk patients identified by the Korean predictive model could be prevented by multiple prophylactic antiemetics. A total of 2,456 patients were selected from our previous PONV study and assigned to the control group, and ..
  41. ncbi 5-HT3 receptor antagonists for prevention of late acute-onset emesis
    Manuel Constenla
    Complejo Hospitalario de Pontevedra, C Loureiro Crespo, 2, 36001 Pontevedra, Spain
    Ann Pharmacother 38:1683-91. 2004
    ..To review the currently available literature on the efficacy of the 5-HT(3) receptor antagonists in the prevention of late acute-onset chemotherapy-induced nausea and vomiting (12-24 h after cytotoxic treatment)...
  42. ncbi Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist
    Rudolph M Navari
    Indiana University School of Medicine, Notre Dame Cancer Institute, South Bend, IN 46617, USA
    Future Oncol 2:591-602. 2006
    ..Future studies may consider the use of palonosetron with current and other new agents and in other clinical settings, such as bone marrow transplantation and radiation therapy...
  43. ncbi Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Matti Aapro
    Clinique de Genolier, 1272, Genolier, Switzerland
    Curr Med Res Opin 21:885-97. 2005
    ..The PubMed search engine was used to search for relevant literature (up to December 2004) and relevant international congress materials collected during 2003 and 2004...
  44. pmc Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy
    Enzo Ballatori
    Medical Statistics Unit, Dept of Internal Medicine and Public Health, University, P Tommasi 2, L Aquila, Italy
    Health Qual Life Outcomes 1:46. 2003
    ....
  45. ncbi A comparison of three antiemetic combinations for the prevention of postoperative nausea and vomiting
    M J Sanchez-Ledesma
    Department of Anesthesiology and Critical Care, University Clinic, School of Medicine, University of Navarra, Pamplona, Spain
    Anesth Analg 95:1590-5, table of contents. 2002
    ....
  46. ncbi Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting
    P Diemunsch
    Department of Anesthesiology, Hautepierre University Hospital, 1 Avenue Moliere, Strasbourg, France
    Br J Anaesth 103:7-13. 2009
    ..generator responsible for emesis and the central role of substance P, led to the development of a new class of antiemetics: the neurokinin-1 (NK1) receptor antagonists...
  47. ncbi The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: a preliminary report
    Ashraf S Habib
    Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Anesth 17:62-5. 2005
    ..To compare the effectiveness of treating established postoperative nausea and vomiting (PONV) with an antiemetic acting at a different receptor with that of treating PONV with the antiemetic used for prophylaxis...
  48. ncbi Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study
    Christopher M Booth
    Toronto Sunnybrook Regional Cancer Centre and Princess Margaret Hospital, Toronto, Canada
    J Support Oncol 5:374-80. 2007
    ..data documenting the prevalence and severity of emesis in patients with breast cancer in the era of modern antiemetics. This prospective multicenter study evaluated chemotherapy-induced nausea and vomiting (CINV) in patients with ..
  49. ncbi Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials
    Nadia Salvo
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Int J Radiat Oncol Biol Phys 82:408-17. 2012
    ..To systematically review the effectiveness and safety of 5-hydroxytryptamine-3 receptor antagonists (5-HT3 RAs) compared with other antiemetic medication or placebo for prophylaxis of radiation-induced nausea and vomiting...
  50. ncbi Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study
    Y E Moon
    Department of Anaesthesiology and Pain Medicine, Seoul St Mary s Hospital, Catholic University College of Medicine, Seoul, Republic of Korea
    Br J Anaesth 108:417-22. 2012
    ..This study compared the effects of i.v. ondansetron and palonosetron administered at the end of surgery in preventing postoperative nausea and vomiting (PONV) in high-risk patients receiving i.v. PCA after thyroidectomy...
  51. ncbi The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
    Deborah L Keefe
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 7:65-72. 2002
    ..To review and evaluate the potential cardiac effects of 5-HT(3) antiemetic treatment in patients who may be predisposed to cardiac complications resulting from malignancy, cytotoxic oncologic regimens, or preexisting comorbid conditions...
  52. pmc Opportunities for the replacement of animals in the study of nausea and vomiting
    A M Holmes
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, W1B 1AL, UK
    Br J Pharmacol 157:865-80. 2009
    ..We provide suggestions for how these limitations may be overcome using non-animal alternatives, including greater use of human volunteers, in silico and in vitro techniques and lower organisms...
  53. ncbi Undertreatment of nausea and other symptoms in hospitalized cancer patients
    Judi Greaves
    Palliative Care, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, Australia
    Support Care Cancer 17:461-4. 2009
    ..This survey aimed to provide a symptom profile, in particular for nausea and its treatment, of advanced cancer patients prior to implementation of a clinical practice guideline for nausea...
  54. ncbi Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers
    Anup K Majumdar
    Merck Research Laboratories, West Point, PA, USA
    J Clin Pharmacol 46:291-300. 2006
    ..Consistent daily plasma exposures of aprepitant were obtained following this regimen, which was generally well tolerated...
  55. ncbi A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting
    Ching Liang Ho
    Division of Hematology Oncology, Tri Service General Hospital, Taipei, Taiwan
    Jpn J Clin Oncol 40:294-301. 2010
    ..To evaluate the efficacy of intravenous ramosetron plus dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting...
  56. ncbi Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment
    Sung Wan Kim
    Department of Psychiatry, Chonnam National Univ Hospital, 8 Hak Dong, Dong Ku, Kwangju 501 757, Republic of Korea
    Psychosomatics 47:440-2. 2006
    ..This is the first report to show that mirtazapine may be an effective alternative when gastroparesis is refractory to conventional measures...
  57. ncbi The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
    F D Tattersall
    Department of Pharmacology, Merck, Sharp and Dohme, Neuroscience Research Centre, Harlow, Essex, UK
    Neuropharmacology 39:652-63. 2000
    ....
  58. pmc Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial
    Jan Wallenborn
    Department of Anaesthesiology and Intensive Care Medicine, University of Leipzig, D 04103 Leipzig, Germany
    BMJ 333:324. 2006
    ....
  59. ncbi Electrocardiographic findings of palonosetron in cancer patients
    Guzin Gonullu
    Medical Oncology Department, Ondokuz Mayis University, Samsun, Turkey
    Support Care Cancer 20:1435-9. 2012
    ..Several studies have shown that these agents cause certain ECG changes. We aimed to evaluate the ECG changes caused by palonosetron, one of the new 5-HT(3) antagonists...
  60. ncbi Risk factors for severe postoperative nausea and vomiting in a randomized trial of nitrous oxide-based vs nitrous oxide-free anaesthesia
    K Leslie
    Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Grattan St, Parkville, Vic, 3050, Australia
    Br J Anaesth 101:498-505. 2008
    ..As risk stratification may aid in prophylaxis and treatment, we explored risk factors for severe PONV in patients enrolled in a large international, randomized controlled trial (the ENIGMA trial)...
  61. ncbi Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial
    John J Reeves
    Department of Pediatric Emergency Medicine, University Medical Center, Las Vegas, Nevada 89102, USA
    Pediatrics 109:e62. 2002
    ..The objective of this study was to evaluate the efficacy of ondansetron for the treatment of vomiting associated with acute gastroenteritis in children...
  62. ncbi Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting
    Peter Kranke
    University Hospitals of Würzburg, Department of Anaesthesiology, D 97080 Wurzburg, Germany
    Expert Opin Pharmacother 8:3217-35. 2007
    ..Treatment remains a most important pillar and there is evidence that the principles of combining antiemetics to prolong effects and improve protection can be similarly applied to treatment...
  63. ncbi The use of an anesthesia information management system for prediction of antiemetic rescue treatment at the postanesthesia care unit
    A Junger
    Department of Anesthesiology and Intensive Care Medicine, Justus Liebig University, Rudolf Buchheim Str 7, D 35392 Giessen, Germany
    Anesth Analg 92:1203-9. 2001
    ..18; use of N(2)O, OR = 2.24; and IV anesthesia with propofol, OR = 0.40) are predictive. In implementing an equation for risk calculation into the AIMS, the individual risk of PONV can be calculated automatically...
  64. ncbi Drugs for preventing postoperative nausea and vomiting
    J B Carlisle
    NHS, Department of Anaesthetics, Torbay Hospital, Lawes Bridge, Torquay, Devon, UK EX6 7LU
    Cochrane Database Syst Rev 3:CD004125. 2006
    ..Drugs can prevent postoperative nausea and vomiting, but their relative efficacies and side effects have not been compared within one systematic review...
  65. ncbi The impact of chemotherapy-induced nausea and vomiting on health-related quality of life
    Enzo Ballatori
    Medical Statistics Unit, Department of Internal Medicine and Public Health, University of L Aquila, Via Pillino 2, 63030, Spinetoli AP, Italy
    Support Care Cancer 15:179-85. 2007
    ....
  66. ncbi The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial
    R de Wit
    Rotterdam Cancer Institute and Erasmus University Medical Center, PO Box 5201, 3008, Rotterdam, The Netherlands
    Eur J Cancer 40:403-10. 2004
    ..alone (a 5-HT(3) antagonist plus dexamethasone), those who received aprepitant in addition to standard therapy had consistently better antiemetic protection that was well maintained over multiple cycles of highly emetogenic chemotherapy..
  67. ncbi American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
    Mark G Kris
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 24:2932-47. 2006
    To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology. UPDATE METHODOLOGY: The Update Committee completed a review and analysis of data published from 1998 thru February 2006...
  68. ncbi Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-contr
    Steven M Grunberg
    University of Vermont, Burlington, VT 05405, USA
    Lancet Oncol 10:549-58. 2009
    ....
  69. ncbi Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting
    Francesca Borrelli
    Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy
    Obstet Gynecol 105:849-56. 2005
    Conventional antiemetics are burdened with the potential of teratogenic effects during the critical embryogenic period of pregnancy. Thus, a safe and effective medication would be a welcome addition to the therapeutic repertoire...
  70. ncbi Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients
    Pierre Benoit Tremblay
    Institute of Clinical Pharmacology and Department of Hematology and Oncology, University Medical Center Charite, Humboldt University of Berlin, Berlin, Germany
    J Clin Oncol 21:2147-55. 2003
    ..The 5-HT3B subunit seems to be most important for its functionality. We hypothesized that patients with genetic variations in the 5-HT3B receptor gene might respond differently to antiemetic treatment...
  71. ncbi Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations
    Karin Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Oncologist 12:1143-50. 2007
    ..With the correct use of antiemetics, CINV can be prevented in almost 70% to up to 80% of patients...
  72. ncbi Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
    Steven M Grunberg
    Division of Hematology Oncology, Vermont Cancer Center, 89 Beaumont Avenue Given Bldg E214, Burlington, VT 05405, USA
    Support Care Cancer 17:589-94. 2009
    ..The present study evaluated a more convenient single-day three-drug antiemetic regimen for patients receiving moderately emetogenic chemotherapy...
  73. ncbi Incidence of chemotherapy-induced nausea and emesis after modern antiemetics
    Steven M Grunberg
    Department of Medicine, University of Vermont, Burlington, Vermont 05401, USA
    Cancer 100:2261-8. 2004
    ..They also assessed whether physicians and nurses accurately recognized the incidence of acute and delayed CINV in their own practices...
  74. ncbi Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States
    Chris Craver
    Premier, Inc, Charlotte, NC, USA
    J Med Econ 14:87-98. 2011
    ....
  75. ncbi The effect of an anatomically classified procedure on antiemetic administration in the postanesthesia care unit
    Joseph R Ruiz
    Department of Anesthesiology and Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Anesth Analg 110:403-9. 2010
    ..Our goal in this retrospective database study was to investigate the effect the type of surgical procedure (categorized and compared anatomically) has on antiemetic therapy within 2 h of admission to the postanesthesia care unit (PACU)...
  76. ncbi Managing nausea and vomiting after cancer treatments: patients still suffer unnecessarily
    Alexander Molassiotis
    Eur J Oncol Nurs 9:4-5. 2005
  77. ncbi Less postoperative nausea and vomiting after propofol + remifentanil versus propofol + fentanyl anaesthesia during plastic surgery
    P Rama-Maceiras
    Department of Anaesthesiology and Perioperative Medicine, Complejo Hospitalario Universitario Juan Canalejo, 15006 A Coruna, Spain
    Acta Anaesthesiol Scand 49:305-11. 2005
    ....
  78. ncbi Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR
    Wendong Huang
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 18:2402-8. 2004
    ..These results demonstrate that a single compound can induce opposite xenobiotic responses via orthologous receptors in rodents and humans...
  79. ncbi Comparison of prophylactic anti-emetic effects of ondansetron and dexamethasone in women undergoing day-case gynaecological laparoscopic surgery
    M S Yuksek
    Department of Anaesthesiology and Reanimation, Ataturk University, Erzurum, Turkey
    J Int Med Res 31:481-8. 2003
    ..In conclusion, ondansetron, but not dexamethasone, prevented PONV in the first 3 h after gynaecological laparoscopic surgery...
  80. ncbi Aprepitant (EMEND): the role of substance P in nausea and vomiting
    Eric Prommer
    UCLA School of Medicine, Division of Hematology Oncology, Los Angeles, CA 90073, USA
    J Pain Palliat Care Pharmacother 19:31-9. 2005
    ..Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting...
  81. ncbi Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea
    Cheryl L Limebeer
    Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario, Canada N2L 2C5
    Physiol Behav 88:398-403. 2006
    ....
  82. ncbi Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy
    Mayako Uchida
    Department of Pharmacy, Kyushu University Hospital KUH, Fukuoka, Japan
    Am J Health Syst Pharm 70:343-9. 2013
    ..Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated...
  83. ncbi Placental transfer of ondansetron during early human pregnancy
    Shing Shun N Siu
    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Clin Pharmacokinet 45:419-23. 2006
    ..Ondansetron had been used in pregnant women when treatment with conventional antiemetics has failed; however, the safety and tolerability of this relatively new antiemetic drug during pregnancy is ..
  84. ncbi New antiemetic drugs
    F Roila
    Medical Oncology Division, Silvestrini Hospital, Perugia, Italy
    Ann Oncol 17:ii96-100. 2006
    ..Important progress in the prophylaxis of chemotherapy-induced acute and delayed emesis has been achieved but some fundamental needs still remain that requires new, efficacious antiemetic drugs...
  85. ncbi The effects of manipulating expectations through placebo and nocebo administration on gastric tachyarrhythmia and motion-induced nausea
    Max E Levine
    Wake Forest University School of Medicine, Department of Internal Medicine, Section of Gastroenterology, Medical Center Boulevard, Winston Salem, North Carolina 27157, USA
    Psychosom Med 68:478-86. 2006
    ..The purpose of this study was to examine the effects of manipulating expectations through the administration of placebos and nocebos on nausea and gastric tachyarrhythmia provoked by a rotating optokinetic drum...
  86. doi The effects of antiemetics for children with vomiting due to acute, moderate gastroenteritis
    Rachel C Vreeman
    Children s Health Services Research, Department of Pediatrics, Indiana University School of Medicine, 410 W 10th St, HITS 1020, Indianapolis, IN 46202, USA
    Arch Pediatr Adolesc Med 162:866-9. 2008
  87. ncbi Effect of acupuncture on nausea and/or vomiting during and after cesarean section in comparison with ondansetron
    Alaa M El-Deeb
    Department of Anesthesiology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
    J Anesth 25:698-703. 2011
    ..This study compared the effect of electrical acustimulation with ondansetron for preventing intraoperative and postoperative emetic symptoms and improving patient satisfaction...
  88. pmc Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles
    R de Wit
    Department of Medical Oncology, Rotterdam Cancer Institute and University Hospital, The Netherlands
    Br J Cancer 77:1487-91. 1998
    ....
  89. ncbi Chronic severe dystonia after single exposure to antiemetics
    Melanie Walker
    Department of Neurology, University of Washington, Seattle, 98104, USA
    Am J Emerg Med 24:125-7. 2006
  90. ncbi Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results
    V Lorusso
    Oncology Unit, Vito Fazzi Hospital, Lecce, Italy
    Support Care Cancer 17:1469-73. 2009
    ..Moreover, we evaluated the amount of their food intake (FI) in the week following therapy, in order to measure any reduction of calories consumption related to Chemotherapy-induced nausea and vomiting (CINV)...
  91. ncbi A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period
    Anthony L Kovac
    Department of Anesthesiology, University of KS Medical Center, Kansas City, KS, USA
    Anesth Analg 107:439-44. 2008
    ....
  92. ncbi A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics
    Eric S Hsu
    Department of Anesthesiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Am J Ther 17:476-86. 2010
    ..Prophylactic and therapeutic combinations of antiemetics are recommended in patients at high risk of suffering from PONV and postdischarge nausea and vomiting...
  93. ncbi Antiemetic placebo: reduce adverse drug interactions between chemotherapeutic agents and antiemetic drugs in cancer patients
    Zhongyi Zhang
    Department of Clinical Pharmacology, Second Medical College, Southern Medical University, Guangzhou, China
    Med Hypotheses 70:551-5. 2008
    ....
  94. ncbi [Postoperative nausea and vomiting--what's new in anti-emetic pharmacotherapy?]
    Jan Wallenborn
    Klinik und Poliklinik fürAnästhesiologie und Intensivtherapieam UK Leipzig
    Anasthesiol Intensivmed Notfallmed Schmerzther 44:296-304; quiz 305. 2009
    ..the prevention of postoperative nausea and vomiting (PONV) and show an efficacy comparable with those of common antiemetics with some evidence for superiority with regard to vomiting...
  95. ncbi Efficacy of orally disintegrating ondansetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomised, double-blind placebo controlled study
    V K Grover
    Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Anaesthesia 64:595-600. 2009
    ..In conclusion, orally disintegrating ondansetron was as efficacious as intravenous ondansetron in the peri-operative phase and may be a viable option for prophylaxis of emesis in day care surgery...
  96. ncbi Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy
    David G Warr
    Princess Margaret Hospital, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Support Care Cancer 19:807-13. 2011
    ....
  97. ncbi Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009
    Karin Jordan
    Department of Medical Oncology and Hematology, University of Halle, Ernst Grube Strasse 40, Halle, Germany
    Support Care Cancer 19:S37-42. 2011
    ....
  98. ncbi Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study
    Antonio Rozzi
    Clinical Oncology Unit, Istituto Neurotraumatologico Italiano, Grottaferrata, Rome, Italy
    Support Care Cancer 19:697-701. 2011
    ..The aim of the present study was to investigate the efficacy of palonosetron for prevention of CINV-induced by adjuvant TMZ...
  99. ncbi Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy
    Anu Kochanujan Pillai
    College of Nursing, All India Institute of Medical Sciences, New Delhi, India
    Pediatr Blood Cancer 56:234-8. 2011
    ..Ginger has been used in postoperative and pregnancy-induced nausea and vomiting. Data on its utility in reducing CINV in children and young adults are lacking...
  100. ncbi Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
    Paul J Hesketh
    Medical Oncology, St Elizabeth s Medical Center, Boston, MA 02135, USA
    Support Care Cancer 18:1171-7. 2010
    ....
  101. ncbi Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics
    Jeremy Stapleton
    Division of Gastroenterology Hepatology, Department of Medicine, University of Louisville School of Medicine, 550 S Jackson Street, ACB 3rd Floor, Louisville, KY 40202, USA
    Gastrointest Endosc Clin N Am 19:57-72, vi. 2009
    ..The purpose of this review is to provide an update on the use of antiemetics, prokinetics, and tricyclics for the treatment for nausea and vomiting associated with gastroparesis.

Research Grants61

  1. Structure of the GABA-A Receptor Binding Sites
    CYNTHIA M CZAJKOWSKI; Fiscal Year: 2012
    ..abstract_text> ..
  2. Structure of the GABA-A Receptor Binding Sites
    CYNTHIA M CZAJKOWSKI; Fiscal Year: 2013
    ....
  3. Pharmacological modulation of synapses and cognition during HIV-1 neurotoxicity
    Stanley A Thayer; Fiscal Year: 2013
    ..and cognitive recovery, this result would caution against recreational use of cannabinoids or their use as antiemetics and appetite stimulants in patients with HAND...
  4. Treating Chemotherapy Induced Nausea with Acupressure
    Suzanne Dibble; Fiscal Year: 2003
    ..All participants will continue to receive their Western medical care, but the added value of acupressure will be explored. ..
  5. PHARMACOLOGY OF LEUCOVORIN IN CANCER CHEMOTHERAPY
    Douglas Greene; Fiscal Year: 1980
    ..protein binding of leucovorin and drug-drug interactions between leucovorin and methotrexate, antibiotics, antiemetics and other anti-neoplastic agents...
  6. Transmucosal oral diphenhydramine-rapid relief of nausea
    EDWARD CONE; Fiscal Year: 2001
    ..Although many antiemetics are available for use, nearly all are administered by oral ingestion with slow onset of effects...
  7. CANCER CENTER CALGB PARTICIPATION
    Hyman Muss; Fiscal Year: 2002
    ..Committee, is currently developing a clinical protocol that will compare cost with symptom control for antiemetics. Dr...
  8. INTESTINAL ION TRANSPORT--SUBMUCOUS NEURONS
    Annmarie Surprenant; Fiscal Year: 1992
    ..These studies will help to identify submucosal neurones which participate in the pathophysiology of enterotoxins, such as cholera and salmonella...
  9. MECHANISMS OF CANNABINOID'S ANTIEMETIC ACTIONS
    NISSAR DARMANI; Fiscal Year: 2007
    ..9- Tetrahydrocannabinol ((9-THC) and its synthetic analog, nabilone, are effective antiemetics against chemo- and radiotherapy, and patients who are protected during the immediate phase also respond well ..
  10. Outcomes After ACL Reconstruction: Femoral Nerve Block
    Brian Williams; Fiscal Year: 2005
    ..The methods learned and the model developed herein will be the basis of future studies funded through the R01 mechanism. ..
  11. Methylated Genes as Serum Biomarkers for Lung Cancer
    Mark Kris; Fiscal Year: 2008
    ..Future studies will be required to establish this technique as a reliable diagnostic tool to guide the management of patients with lung cancer. ..
  12. MECHANISMS OF CANNABINOIDS ANTIEMETIC ACTIONS
    NISSAR DARMANI; Fiscal Year: 2001
    ..The results will define an important role for the cannabinoid receptors in the vomiting circuits and may implicate an antiemetic role for the endogenous cannabinoids. ..
  13. Patient Expectations and Chemotherapy-Induced Nausea
    Joseph Roscoe; Fiscal Year: 2007
    ..We seek to find out if interventions that increase patients' positive expectancy for nausea prevention can enhance the efficacy of the wristbands and contribute to a reduction in patient nausea. ..
  14. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..
  15. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2007
    ..abstract_text> ..
  16. ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME
    Michael Camilleri; Fiscal Year: 2008
    ..Significance: This project will characterize pharmacogenetic mechanisms determining the response to clonidine through studies of candidate genes that control alpha2-adrenoreceptor function and norepinephrine transport in IBS. ..
  17. Comprehensive Database on Spirituality and Health
    Jeanette Ezzo; Fiscal Year: 2004
    ..Phase II will focus on comprehensively populating the database with a significantly larger and more comprehensive set of research citations and related materials and migrating to a fully functional website, SpiritLit.com. ..
  18. Immune Reconstitution in Nonhuman Primates
    Thomas Macvittie; Fiscal Year: 2005
    ..Clearly the ability to colonize mucosal surfaces in the respiratory, intestinal, and genital tracts also require the orchestrated synthesis of fimbriae for adherence and flagella for motility. ..
  19. Ethanol and mesolimbic GABAergic neurons
    Jiang Hong Ye; Fiscal Year: 2007
    ..Such results will provide valuable information on novel mechanisms underlying the addictive properties of alcohol and a firm scientific foundation for future neurobiological studies. [unreadable] [unreadable] [unreadable]..
  20. Effects of Amino Acid Therapy on Hot Flashes in Postmenopausal Women
    Thomas Guttuso; Fiscal Year: 2007
    ..The applicant will also attend two didactic training seminars in complementary & alternative medicine at The Osher Institute at Harvard Medical School and at the Duke Center for Integrative Medicine. ..
  21. DIZZINESS IN OLDER PEOPLE
    Robert Baloh; Fiscal Year: 2006
    ..By continuing this longitudinal study of carefully studied older patients and controls, our multidisciplinary research team is in a good position to achieve our goals. ..
  22. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  23. C elegans:a model to study intestinal water-soluble vitamins transport in vivo
    HAMID SAID; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  24. The Status and Future of Acupuncture Research: 10 Years Post-NIH Consensus Confer
    Lixing Lao; Fiscal Year: 2007
    ..The proposed conference will do so. [unreadable] [unreadable] [unreadable] [unreadable]..
  25. Palliative Care Curriculum for 3rd-Year Medical Students
    Charles von Gunten; Fiscal Year: 2007
    ..Data will be compared with residents who have not been through the course as well as with residents and faculty participating in another study of education. ..
  26. Sleep/Wake Contiuum in Lewy Body Disease
    Donald L Bliwise; Fiscal Year: 2010
    ..The proposed work will also provide important clinical insights into disease correlates and disease course across the broad spectrum of Parkinsonism. ..
  27. Academic Palliative Care
    Charles von Gunten; Fiscal Year: 2008
    ..All reentered investigators are seeking NCI funding and have the potential to become independent investigators. ..
  28. Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
    Sharon Walsh; Fiscal Year: 2008
    ..This study will provide preliminary safety and efficacy data on the potential utility of atomoxetine and determine whether a larger-scale evaluation is warranted. [unreadable] [unreadable] [unreadable]..
  29. Mechanism/regulation of human intestinal thiamin uptake
    HAMID SAID; Fiscal Year: 2008
    ..This should ultimately assist us in the designing of effective strategies to optimize thiamin body homeostasis in conditions associated with thiamin deficiency and sub-optimal levels. ..
  30. New Neural Targets for Opioid Use Disorders: Human Studies
    Sharon L Walsh; Fiscal Year: 2010
    ..Thus, these studies, conducted in healthy humans, will provide fundamental information regarding the potential for this system as a target for development of new treatment agents for opioid use disorders. ..
  31. Evaluation of Novel Treatments for Stimulant Dependence
    Sharon Walsh; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  32. Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer
    YA CHEN SHIH; Fiscal Year: 2008
    ..To estimate the budgetary impact of the emerging pharmacogenomic prognostic and/or predictive tests [unreadable] [unreadable] [unreadable]..
  33. Combining Antidepressants to Hasten Remission from Depression
    Pierre Blier; Fiscal Year: 2010
    ....
  34. Polysomnographic Assessment of Alternative Treatment
    Donald Bliwise; Fiscal Year: 2006
    ..abstract_text> ..
  35. Diseases of the Vestibular System
    Robert Baloh; Fiscal Year: 2006
    ..abstract_text> ..
  36. Biologic therapy of Melanoma and Renal Cell Cancer
    Michael Atkins; Fiscal Year: 2006
    ..abstract_text> ..
  37. Increased Access to Emergency Contraceptive Pills
    Elizabeth Raymond; Fiscal Year: 2004
    ..These secondary analyses should help explain the primary biologic outcomes and should be useful in the development of counseling messages and service protocols in the future. ..
  38. Enteric Nervous System 2003
    Keith Sharkey; Fiscal Year: 2003
    ..From this picture there will be gaps - these are the challenges for the future. ..
  39. SPECIAL POPULATIONS NETWORK FOR CANCER CONTROL
    Edith Mitchell; Fiscal Year: 2003
    ..abstract_text> ..
  40. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  41. CARDINAL BERNARDIN CANCER CENTER, LOYOLA UNIVERSITY
    Patrick Stiff; Fiscal Year: 2002
    ..At the completion of this grant, the Cardinal Bernardin Cancer Center plans to be positioned to successfully apply for a P-30 Cancer Center Support Grant. ..
  42. ETHANOL EFFECTS ON GLYCINE RECEPTOR/CHANNEL FUNCTION
    Jiang Hong Ye; Fiscal Year: 2003
    ....
  43. SUNDOWN SYNDROME IN A SKILLED NURSING FACILITY
    Donald Bliwise; Fiscal Year: 2002
    ..These results will provide information on the mechanistic basis for sundowning in aged patients with dementing disorders. ..
  44. HEAD CONTROL MECHANISMS DURING VOLUNTARY TRUNK MOVEMENTS
    Timothy Hain; Fiscal Year: 2002
    ..The comparison of intact and BVL populations will elucidate why some persons with BVL recover relatively high functional levels, and others do not. ..
  45. THERAPEUTIC POTENTIAL OF KAPPA-OPIOIDS AGAINST COCAINE
    Sharon Walsh; Fiscal Year: 2002
    ..These studies are relevant to the treatment of cocaine abuse and may lead to the development of an effective pharmacotherapy, thereby, reducing the HIV and other health risks associated with cocaine abuse and intravenous drug abuse. ..
  46. Music Therapy for Cancer Patients at the End of Life
    Kristine Nelson; Fiscal Year: 2004
    ....
  47. Oral Care and Respiratory Pathogen Colonization
    Ozan Akca; Fiscal Year: 2004
    ..Reducing respiratory pathogen colonization in the mouth could significantly reduce the morbidity and cost of VAP. ..
  48. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  49. Neurobiol mechanism/acupuncture therapy/alcoholism
    Jiang Hong Ye; Fiscal Year: 2004
    ..This new knowledge will have a major impact on our understanding of how acupuncture works. The application of this knowledge is expected to improve the effectiveness of acupuncture treatment in alcohol addiction. ..
  50. Optotrack Motion Analysis System
    Timothy Hain; Fiscal Year: 2005
    ..Motion analysis equipment is critical to all of our research faculty, and we have also recently added investigators to the department who need motion analysis capabilities. ..
  51. Factors in Drug Dependence
    Sharon Walsh; Fiscal Year: 2005
    ..abstract_text> ..
  52. The Effect of Sedation on Restorative Sleep
    Avery Tung; Fiscal Year: 2005
    ..Knowledge from this proposal will provide scientific insight into the relationships between anesthesia and sleep, and may lead to more effective clinical use of ICU sedatives. ..
  53. Biomarkers of Aging in the Bay Area Sleep Cohort
    Donald Bliwise; Fiscal Year: 2005
    ..abstract_text> ..
  54. BIFUNCTIONAL OPIOID/CCK LIGANDS FOR PAIN
    Frank Porreca; Fiscal Year: 2006
    ..This novel mechanism of action should yield therapeutic utility as well as provide an increased understanding of opioid-CCK interactions in normal and pathological pain states. ..
  55. Optical Intrinsic Signal Imaging of Seizure
    James Chen; Fiscal Year: 2006
    ..This project will be conducted at the UCLA School of Medicine under Drs. Toga and Wasterlain's guidance. Both mentors are internationally known authorities in their respective fields of research. ..
  56. MITOCHONDRIAL DNA ANALYSIS IN CYCLIC VOMITING SYNDROME
    Richard Boles; Fiscal Year: 2002
    ..An extensive amount of clinical and laboratory data will be collected in all patients, allowing for the comparison of CVS sufferers with and without mtDNA mutations. ..
  57. Treatment of Older Patients with Early Breast Cancer
    Arash Naeim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  58. Prenatal Corticosteroid Impact on Hippocampus
    LIBOR VELISEK; Fiscal Year: 2004
    ..The data of this proposal will be critical for determining long-term adverse effects of multiple course prenatal corticosteroid therapy and for the ameliorating these effects in the offspring. ..
  59. SEXUAL DIMORPHISM IN SEIZURE CONTROL
    JANA VELISKOVA; Fiscal Year: 2002
    ..Rats of both sexes and various ages will be used. These studies may lead to the development of new antiepileptic treatments that take into the account sexual age-related differences. ..
  60. Opioid and Non-Opioid Actions of Dynorphin in Pain
    Frank Porreca; Fiscal Year: 2005
    ..As most clinical conditions of neuropathic pain are treated in the post-injury (i.e., maintenance) state, such information may allow approaches to limit or reverse the pathological actions of dynorphin in maintaining neuropathic pain. ..